{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023489","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.914967+00:00","generated_at":"2026-05-17T13:58:05.559601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials","bullets":["Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.","LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.","LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.","LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.","Cash runway extends at least into June 2026; no quarterly earnings call planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023489","json":"https://secwatch.observer/filing/0001641172-25-023489.json","markdown":"https://secwatch.observer/filing/0001641172-25-023489.md","text":"https://secwatch.observer/filing/0001641172-25-023489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/0001641172-25-023489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:05.559601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}